LongGame Ventures: Company Profile

Background

Overview

LongGame Ventures is a venture capital firm dedicated to funding radical lifespan extension through investments in longevity biotechnology. Established in 2024, the firm focuses on scalable solutions that aim to significantly extend healthy human lifespans, targeting at least a 10-year increase. Their mission is to back bold innovations addressing the root causes of aging, with a vision to make longevity accessible to all.

Mission and Vision

• Mission: To fund companies developing technologies that can meaningfully prolong human life, ensuring these advancements are scalable and accessible to everyone.

• Vision: To pioneer a future where extended, healthy lifespans are a reality for all, redefining medicine and human potential.

Primary Area of Focus

LongGame Ventures specializes in longevity biotechnology, investing in early-stage biotech startups that are developing innovative solutions to extend healthy human lifespans. Their focus areas include regenerative medicine, cellular replacement, and interventions aimed at reprogramming the biology of aging.

Industry Significance

The firm operates in the rapidly evolving field of longevity biotech, which is gaining significant attention due to breakthroughs in areas like AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, and tissue engineering. As global demographics shift towards aging populations, the demand for longevity interventions is expected to grow, presenting a substantial market opportunity.

Key Strategic Focus

Core Objectives

• Radical Lifespan Extension: Investing in technologies with the potential to extend healthy human lifespans by at least 10 years.

• Scalability and Accessibility: Ensuring that longevity solutions are scalable and accessible to a broad population, not just the wealthy.

• Evidence-Based Investments: Prioritizing companies with strong ethical foundations and robust scientific backing.

Specific Areas of Specialization

• Regenerative Medicine: Developing therapies that regenerate or replace damaged tissues and organs.

• Cellular Replacement: Innovating methods to replace or rejuvenate aging cells.

• Biological Reprogramming: Interventions aimed at reprogramming the biology of aging to restore youthful function.

Key Technologies Utilized

• Synthetic Biology: Engineering biological systems for therapeutic purposes.

• Gene and Cell Therapies: Modifying genes or cells to treat or prevent diseases associated with aging.

• AI-Driven Discovery: Leveraging artificial intelligence to accelerate drug discovery and development processes.

Primary Markets or Conditions Targeted

LongGame Ventures targets conditions associated with aging, including neurodegenerative diseases, cardiovascular diseases, and other age-related health issues. The firm aims to address the root causes of aging, thereby improving overall healthspan and quality of life.

Financials and Funding

Funding History

In December 2024, LongGame Ventures launched a $40 million venture capital fund dedicated to advancing longevity biotechnology. The fund focuses on early-stage biotech startups developing scalable technologies to extend healthy human lifespans.

Notable Investors

While specific investors in LongGame Ventures' fund are not publicly disclosed, the firm has established partnerships with organizations such as Carey Olsen, which advised on the fund's launch.

Intended Utilization of Capital

The capital is intended to support early-stage biotech startups in developing and scaling technologies that can significantly extend healthy human lifespans. The firm emphasizes bridging biotechnology with decentralized science, fostering collaboration between traditional life sciences and emerging decentralized technologies.

Pipeline Development

Key Pipeline Candidates

LongGame Ventures has invested in several promising biotech companies, including:

• Deciduous Therapeutics: Pioneering a therapeutic strategy that leverages immune activation to eliminate senescent cells, addressing age-related diseases.

• Lucis: A preventive, personalized, and science-based health company aiming to help Europeans live up to 100 healthy years.

• Vincere Biosciences: Developing mitophagy-enhancing therapies with applications in neurodegeneration and skin longevity.

Stages of Clinical Trials or Product Development

Specific details on the stages of clinical trials or product development for these companies are not publicly disclosed.

Target Conditions

The target conditions for these pipeline candidates include age-related diseases such as neurodegenerative disorders, cardiovascular diseases, and other health issues associated with aging.

Relevant Timelines for Anticipated Milestones

Anticipated milestones for these companies are not publicly disclosed.

Technological Platform and Innovation

Proprietary Technologies

LongGame Ventures focuses on investing in companies developing proprietary technologies in areas such as synthetic biology, gene and cell therapies, and AI-driven drug discovery. While the firm does not develop its own proprietary technologies, it plays a crucial role in identifying and supporting innovative solutions in the longevity biotech space.

Significant Scientific Methods

• Synthetic Biology: Engineering biological systems for therapeutic purposes.

• Gene and Cell Therapies: Modifying genes or cells to treat or prevent diseases associated with aging.

• AI-Driven Discovery: Leveraging artificial intelligence to accelerate drug discovery and development processes.

AI-Driven Capabilities

LongGame Ventures leverages AI-driven capabilities to identify promising biotech startups and assess the potential impact of their technologies on extending healthy human lifespans. The firm emphasizes the integration of AI in drug discovery processes to enhance efficiency and effectiveness.

Leadership Team

Key Executive Profiles

• Will Harborne: General Partner & Chief Investment Officer. Harborne is a crypto investor who founded LongGame Ventures with the goal of advancing longevity biotechnology.

• Dr. Manish Chamoli: Co-Managing Partner and Chief Scientific Officer. Dr. Chamoli brings deep expertise in aging biology and longevity research from his tenure at the Buck Institute.

• Sebastian A. Brunemeier: Co-Managing Partner. Brunemeier serves as a Special Advisor at Healthspan Capital, contributing to LongGame Ventures' strategic direction.

• Chloe Northcott: Head of Operations. Northcott previously worked at Geometry and now leads operations at LongGame Ventures.

Leadership Changes

As of January 2026, there have been no publicly disclosed significant changes or appointments within LongGame Ventures' leadership team.

Competitor Profile

Market Insights and Dynamics

The longevity biotech market is experiencing rapid growth, driven by advancements in areas such as AI, synthetic biology, stem cell therapies, gene sequencing and editing, protein engineering, and tissue engineering. With aging populations globally, there is an increasing demand for interventions that can extend healthy human lifespans, presenting a substantial market opportunity.

Competitor Analysis

Key competitors in the longevity biotech venture capital space include:

• Healthspan Capital: Led by General Partner Sebastian A. Brunemeier, Healthspan Capital focuses on investments in longevity and healthspan extension.

• Juvenescence: A global biotechnology company developing therapies to modify aging and increase human longevity.

• AgeX Therapeutics: Specializes in the development of therapeutics for age-related diseases and human longevity.

Strategic Collaborations and Partnerships

LongGame Ventures has established strategic collaborations with organizations such as Carey Olsen, which advised on the launch of their longevity biotech fund.

Operational Insights

LongGame Ventures differentiates itself by focusing exclusively on radical lifespan extension, targeting technologies with the potential to extend healthy human lifespans by at least 10 years. The firm emphasizes scalability and accessibility, ensuring that longevity solutions benefit society as a whole. Their integration of decentralized science, including the use of decentralized autonomous organizations (DAOs), aims to streamline drug discovery and foster patient-driven research.